Close Menu

NEW YORK (360Dx) – Clemson University spinout Kiyatec announced today that it has raised $3 million in a Series B2 financing round.

The Greenville, South Carolina-based firm will use the proceeds to further its ongoing clinical study, 3D-Predict, to validate its cell culture platform as a patient-specific predictor of response to cancer therapies for solid tumors. The assay analyzes a patient's live cancer cells to determine whether they respond to guideline-recommended cancer drugs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.